For Pet Insurance Partners

Genomic medicine, for the pets your policyholders love.

AnticiPet brings two decades of advances in human genomic medicine to companion animals — giving insurers a way to differentiate, deepen customer loyalty, and reduce long-term claims through earlier, smarter pet care.

Explore the partnership → How it works
Germline risk Drug response Early signals
100s
Diseases screened
1x
Sample, lifetime use
~50%
US homes with a dog
Whole genome sequencing
Early cancer detection
Organ failure signals
The Market

A $200B industry with a healthcare gap.

Pet owners are spending more than ever on the animals they consider family. But the diagnostic tools available to vets lag decades behind human medicine — and pet insurers feel the cost of that gap every quarter.

Industry size
$200B
Projected U.S. pet care market by 2026 — up from $152B in 2024.
Households
39M
U.S. households own a dog — roughly half of all homes nationwide.
Senior dogs
~50%
Of the dog population is 7+ years old — the segment driving the most claims.
Gen Z investment
1.13%
Of Gen Z income goes to pet care — the highest proportional spend of any generation.
For Pet Insurers

A genuine differentiator in a crowded market.

Most pet insurers compete on price and reimbursement terms. AnticiPet offers something competitors can't easily match: a science-backed benefit that policyholders feel for the life of their pet.

— 01

Stand out where price wars don't work

Bundle genomic insights into policies as a premium benefit. Pet parents get personalized health information; you get a story your competitors aren't telling.

— 02

Lower long-term claims through earlier care

Genomic risk signals and early detection of organ failure or cancer enable preventive interventions — moving care upstream of the expensive end-stage treatments insurers fund today.

— 03

Reach pet parents at scale

Partnership channels reach millions of policyholders directly — far more efficient than building a consumer brand from scratch. Both sides win on customer acquisition cost.

— 04

Deeper customer loyalty

Genomic information becomes more valuable as a pet ages. The benefit creates a lasting reason for policyholders to renew with you, year after year.

— 05

An ecosystem advantage

AnticiPet sits at the hub of pet insurance, nutrition, diagnostics, and veterinary care — coordinated benefits that compound in value for the policyholder.

— 06

Built on proven human-medicine foundations

We don't reinvent genomics. We translate $100B+ of human-medicine R&D — already validated — into a veterinary context, dramatically reducing scientific and timeline risk.

So, as responsible pet owners, we are willing to invest in these aspects of their care, often going above and beyond to ensure their well-being."
Arthur Salisbury · Founder, Pitbulls Home
Product Roadmap

One sample. A lifetime of insight.

A pet parent provides a single sample. AnticiPet sequences and stores it once, then unlocks layers of relevant health information as the pet matures — no genomics knowledge required from the owner or the vet.

I
Phase I · Now

Whole genome sequencing for dogs

Insights into hundreds of inherited disease risks and how a dog will respond to common medications — surfaced when it's relevant to age, breed, and health.

II
Phase II · Next

Early organ-failure detection

Diagnostic tests for emerging liver and kidney disease — catching the conditions that drive the largest senior-pet claims well before they become acute.

III
Phase III · Horizon

Early cancer detection

Bringing the same circulating-DNA approaches transforming human oncology to companion animals — enabling precision treatment when outcomes are best.

Leadership

Built by operators who've done this before.

AnticiPet's team combines decades of experience scaling diagnostics companies with deep scientific credentials in clinical genomics.

Katherine Varley

Katherine Varley, PhD

Scientific Co-Founder

Professor at the University of Utah Huntsman Cancer Institute. Develops molecular methods and bioinformatics to understand how gene regulation goes wrong in cancer — and to find biomarkers that improve treatment.

Research focus Clinical trial genomics · Epigenome engineering · Circulating tumor DNA · Metastasis drivers
Troy Moore

Troy Moore

Co-Founder

A longtime passion — backed by decades of experience — for building life-science companies from concept to operations. Focused on problem solving, development strategy, and revenue generation.

Selected experience Research Genetics · Open Biosystems · ThermoFisher · Kailos Genetics
Guido Baechler

Guido Baechler

Chief Executive Officer

30+ years of global leadership across public and private life-science companies, with a track record of building and scaling diagnostics and biotech businesses from start-up through Nasdaq IPO.

Selected experience Mainz BioMed · Berkeley Life Science Advisors · SummerBio · Singulex · Roche Molecular Systems
Let's talk

Let's build a benefit your competitors can't copy.

We're partnering with a select group of forward-looking pet insurers to bring genomic medicine to their policyholders. If that sounds like you, we'd like to talk.

Start a partnership conversation →
Or email us directly at info@anticipet.bio